These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 32669577)

  • 21. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
    Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
    Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Modulation of TLR9 on anti-tumor immune responses of peripheral blood mononuclear cells from patients with non-small-cell lung cancer].
    Ren T; Cai YY; Liang YJ; Jin ML; Guo ZL; Tao MF; He X
    Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(17):1168-72. PubMed ID: 18844109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunostimulatory Properties of Lipid Modified CpG Oligonucleotides.
    Yu C; An M; Li M; Liu H
    Mol Pharm; 2017 Aug; 14(8):2815-2823. PubMed ID: 28686452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses.
    Merlo A; Calcaterra C; Mènard S; Balsari A
    J Leukoc Biol; 2007 Sep; 82(3):509-18. PubMed ID: 17586660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The STING ligand cGAMP potentiates the efficacy of vaccine-induced CD8+ T cells.
    Gutjahr A; Papagno L; Nicoli F; Kanuma T; Kuse N; Cabral-Piccin MP; Rochereau N; Gostick E; Lioux T; Perouzel E; Price DA; Takiguchi M; Verrier B; Yamamoto T; Paul S; Appay V
    JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Eomes
    Jia B; Zhao C; Rakszawski KL; Claxton DF; Ehmann WC; Rybka WB; Mineishi S; Wang M; Shike H; Bayerl MG; Sivik JM; Schell TD; Drabick JJ; Hohl RJ; Zheng H
    Cancer Res; 2019 Apr; 79(7):1635-1645. PubMed ID: 30709927
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High Levels of Eomes Promote Exhaustion of Anti-tumor CD8
    Li J; He Y; Hao J; Ni L; Dong C
    Front Immunol; 2018; 9():2981. PubMed ID: 30619337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Naïve CD8
    Nicoli F; Papagno L; Frere JJ; Cabral-Piccin MP; Clave E; Gostick E; Toubert A; Price DA; Caputo A; Appay V
    Front Immunol; 2018; 9():2736. PubMed ID: 30619240
    [No Abstract]   [Full Text] [Related]  

  • 29. Harnessing the Induction of CD8
    Nicoli F; Paul S; Appay V
    Front Immunol; 2018; 9():2372. PubMed ID: 30410483
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical and clinical development of neoantigen vaccines.
    Li L; Goedegebuure SP; Gillanders WE
    Ann Oncol; 2017 Dec; 28(suppl_12):xii11-xii17. PubMed ID: 29253113
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunological considerations regarding parental concerns on pediatric immunizations.
    Nicoli F; Appay V
    Vaccine; 2017 May; 35(23):3012-3019. PubMed ID: 28465096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cutting Edge: A Dual TLR2 and TLR7 Ligand Induces Highly Potent Humoral and Cell-Mediated Immune Responses.
    Gutjahr A; Papagno L; Nicoli F; Lamoureux A; Vernejoul F; Lioux T; Gostick E; Price DA; Tiraby G; Perouzel E; Appay V; Verrier B; Paul S
    J Immunol; 2017 Jun; 198(11):4205-4209. PubMed ID: 28432147
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Triggering Intracellular Receptors for Vaccine Adjuvantation.
    Gutjahr A; Tiraby G; Perouzel E; Verrier B; Paul S
    Trends Immunol; 2016 Sep; 37(9):573-587. PubMed ID: 27474233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Priming of Qualitatively Superior Human Effector CD8+ T Cells Using TLR8 Ligand Combined with FLT3 Ligand.
    Lissina A; Briceño O; Afonso G; Larsen M; Gostick E; Price DA; Mallone R; Appay V
    J Immunol; 2016 Jan; 196(1):256-263. PubMed ID: 26608912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential adjuvant activities of TLR7 and TLR9 agonists inversely correlate with nitric oxide and PGE2 production.
    Lee J; Martinez N; West K; Kornfeld H
    PLoS One; 2015; 10(4):e0123165. PubMed ID: 25875128
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN.
    Temizoz B; Kuroda E; Ohata K; Jounai N; Ozasa K; Kobiyama K; Aoshi T; Ishii KJ
    Eur J Immunol; 2015 Apr; 45(4):1159-69. PubMed ID: 25529558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High doses of CpG oligodeoxynucleotides stimulate a tolerogenic TLR9-TRIF pathway.
    Volpi C; Fallarino F; Pallotta MT; Bianchi R; Vacca C; Belladonna ML; Orabona C; De Luca A; Boon L; Romani L; Grohmann U; Puccetti P
    Nat Commun; 2013; 4():1852. PubMed ID: 23673637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Type 1 interferons and antiviral CD8 T-cell responses.
    Welsh RM; Bahl K; Marshall HD; Urban SL
    PLoS Pathog; 2012 Jan; 8(1):e1002352. PubMed ID: 22241987
    [No Abstract]   [Full Text] [Related]  

  • 39. Stimulation and inhibition of FVIII-specific memory B-cell responses by CpG-B (ODN 1826), a ligand for Toll-like receptor 9.
    Allacher P; Baumgartner CK; Pordes AG; Ahmad RU; Schwarz HP; Reipert BM
    Blood; 2011 Jan; 117(1):259-67. PubMed ID: 20889922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Approaches to enhancing immune responses stimulated by CpG oligodeoxynucleotides.
    Mutwiri G; van Drunen Littel-van den Hurk S; Babiuk LA
    Adv Drug Deliv Rev; 2009 Mar; 61(3):226-32. PubMed ID: 19162103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.